Free Trial

Athira Pharma (ATHA) SEC Filings & 10K Form

Athira Pharma logo
$0.29 +0.01 (+2.31%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$0.28 -0.01 (-2.46%)
As of 05/1/2025 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Athira Pharma SEC Filings

DateFilerForm TypeView
04/16/2025
3:22 PM
Athira Pharma (Subject)
Oliveira Steven Michael (Filed by)
Form SCHEDULE 13G
03/12/2025
4:20 PM
Athira Pharma (Issuer)
Renninger Robert (Reporting)
Form 4/A
03/04/2025
3:28 PM
Athira Pharma (Issuer)
Worthington Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
3:29 PM
Athira Pharma (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
3:29 PM
Athira Pharma (Issuer)
Litton Mark James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2025
3:30 PM
Athira Pharma (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/27/2025
3:10 PM
Athira Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
9:21 AM
Athira Pharma (Subject)
BML Investment Partners, L.P. (Filed by)
Form SCHEDULE 13G/A
02/14/2025
8:59 AM
Athira Pharma (Subject)
BML Investment Partners, L.P. (Filed by)
Form SCHEDULE 13G/A
01/02/2025
7:02 PM
Athira Pharma (Subject)
CHURCH KEVIN (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2025
7:04 PM
Athira Pharma (Subject)
Worthington Mark (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2025
7:05 PM
Athira Pharma (Subject)
Litton Mark James (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2025
7:06 PM
Athira Pharma (Subject)
San Martin Javier (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/07/2024
12:15 PM
Athira Pharma (Subject)
BML Investment Partners, L.P. (Filed by)
Form SC 13G
10/31/2024
3:16 PM
Athira Pharma (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SC 13D/A
10/28/2024
11:15 PM
Athira Pharma (Filer)
Form EFFECT
10/21/2024
5:24 AM
Athira Pharma (Filer)
Form S-3
Registration statement under Securities Act of 1933  
10/03/2024
8:50 PM
Athira Pharma (Issuer)
Litton Mark James (Reporting)
Form 4/A
10/03/2024
6:07 PM
Athira Pharma (Issuer)
Litton Mark James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
6:08 PM
Athira Pharma (Issuer)
Worthington Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
6:10 PM
Athira Pharma (Issuer)
CHURCH KEVIN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
6:13 PM
Athira Pharma (Issuer)
San Martin Javier (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
6:17 PM
Athira Pharma (Issuer)
Renninger Robert (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/03/2024
6:05 PM
Athira Pharma (Issuer)
Renninger Robert (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/17/2024
8:00 AM
Athira Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2024
6:47 PM
Athira Pharma (Issuer)
Litton Mark James (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:48 PM
Athira Pharma (Issuer)
Worthington Mark (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:49 PM
Athira Pharma (Issuer)
CHURCH KEVIN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:50 PM
Athira Pharma (Issuer)
Lenington Rachel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:51 PM
Athira Pharma (Issuer)
Gengos Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
6:53 PM
Athira Pharma (Subject)
Litton Mark James (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/01/2024
3:15 PM
Athira Pharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
06/25/2024
6:21 PM
Athira Pharma (Issuer)
Romano Kelly A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2024
3:05 PM
Athira Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
5:54 PM
Athira Pharma (Issuer)
FLUKE JOHN M JR (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
5:55 PM
Athira Pharma (Issuer)
PICKERING GRANT (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
5:56 PM
Athira Pharma (Issuer)
Panzara Michael A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
5:58 PM
Athira Pharma (Issuer)
Kosacz Barbara (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
6:00 PM
Athira Pharma (Issuer)
JOHNSON JAMES A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
6:01 PM
Athira Pharma (Issuer)
EDELMAN JOSEPH (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/24/2024
6:03 PM
Athira Pharma (Issuer)
Romano Kelly A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad)

I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.

All the details are waiting for you now — but you need to act before the May 1st funding window clos
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ATHA) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners